Literature DB >> 35948300

Positivity and Risk Factors for Trichomonas vaginalis Among Women Attending a Sexual Health Clinic in Melbourne, 2006 to 2019.

Esha Abraham, Christopher K Fairley, Ian Denham1, Catriona S Bradshaw, Rebecca M Farquharson, Lenka A Vodstrcil, Erica L Plummer, Jason J Ong, Marcus Y Chen, Tiffany R Phillips, Eric P F Chow.   

Abstract

BACKGROUND: Trichomonas vaginalis is not a notifiable disease in Australia in most states, resulting in limited Australian epidemiological studies. This study aimed to examine the positivity of T. vaginalis in women attending the Melbourne Sexual Health Centre (MSHC) and identify associated factors.
METHODS: All women 16 years or older who were tested for T. vaginalis at MSHC from 2006 to 2019 were included. The diagnostic method changed from culture to nucleic acid amplification test in August 2018. The annual positivity of T. vaginalis was calculated. Because of the data completeness, we performed a generalized estimating equations multivariable logistic regression using data from 2011 to 2019 to examine factors associated with T. vaginalis positivity.
RESULTS: From 2006 to 2019, 69,739 tests for T. vaginalis were conducted, and 294 tested positive (0.42%; 95% confidence interval [CI], 0.37%-0.47%). Approximately 60% of women tested reported symptoms. After adjusting for potential confounders including the change in diagnostic method, there was a 21% (95% CI, 12%-31%) annual increase in T. vaginalis positivity between 2011 and 2019. Women with concurrent syphilis had the highest odds of testing positive for T. vaginalis (adjusted odds ratio [aOR], 21.55; 95% CI, 6.96-66.78), followed by women who had injected drugs in the last 12 months (aOR, 6.99; 95% CI, 4.11-11.87), were 35 years or older (aOR, 3.47; 95% CI, 2.26-5.35), or had concurrent chlamydia (aOR, 1.77; 95% CI, 1.05-2.99).
CONCLUSIONS: The rising positivity of T. vaginalis at MSHC irrespective of change in diagnostic method suggests a concurrent community-wide rise in Melbourne. Given the rising positivity, testing informed by risk factors should be considered.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Sexually Transmitted Diseases Association.

Entities:  

Mesh:

Year:  2022        PMID: 35948300      PMCID: PMC9553257          DOI: 10.1097/OLQ.0000000000001690

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   3.868


  26 in total

1.  Genital Trichomonas vaginalis is rare among female attendees at a Sydney metropolitan sexual health clinic.

Authors:  Donna M Tilley; Sally M Dubedat; Peter Lowe; David J Templeton
Journal:  Aust N Z J Public Health       Date:  2015-11-11       Impact factor: 2.939

Review 2.  Clinical and microbiological aspects of Trichomonas vaginalis.

Authors:  D Petrin; K Delgaty; R Bhatt; G Garber
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

3.  Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples.

Authors:  James P Hughes; Jared M Baeten; Jairam R Lingappa; Amalia S Magaret; Anna Wald; Guy de Bruyn; James Kiarie; Mubiana Inambao; William Kilembe; Carey Farquhar; Connie Celum
Journal:  J Infect Dis       Date:  2012-01-11       Impact factor: 5.226

4.  The Vaginal Infections and Prematurity Study: an overview.

Authors:  J C Carey; S J Yaffe; C Catz
Journal:  Clin Obstet Gynecol       Date:  1993-12       Impact factor: 2.190

5.  Trichomonas vaginalis infection-associated risk of cervical cancer: A meta-analysis.

Authors:  Shaoyan Yang; Weidong Zhao; Huiyan Wang; Yun Wang; Jie Li; Xiao Wu
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2018-06-19       Impact factor: 2.435

6.  Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women.

Authors:  Sue Napierala Mavedzenge; Barbara Van Der Pol; Helen Cheng; Elizabeth T Montgomery; Kelly Blanchard; Guy de Bruyn; Gita Ramjee; Ariane van der Straten
Journal:  Sex Transm Dis       Date:  2010-07       Impact factor: 2.830

7.  A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis.

Authors:  W Wiese; S R Patel; S C Patel; C A Ohl; C A Estrada
Journal:  Am J Med       Date:  2000-03       Impact factor: 4.965

8.  Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women.

Authors:  Melinda B Nye; Jane R Schwebke; Barbara A Body
Journal:  Am J Obstet Gynecol       Date:  2009-02       Impact factor: 8.661

9.  Spatial and Temporal Epidemiology of Infectious Syphilis in Victoria, Australia, 2015-2018.

Authors:  Ei T Aung; Marcus Y Chen; Christopher K Fairley; Nasra Higgins; Deborah A Williamson; Jane E Tomnay; Kathryn A Cook; Joanne Peel; Vino Dharmakulasinghe; Charles Alpren; Eric P F Chow
Journal:  Sex Transm Dis       Date:  2021-12-01       Impact factor: 2.830

10.  Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines.

Authors:  Sami L Gottlieb; Nicola Low; Lori M Newman; Gail Bolan; Mary Kamb; Nathalie Broutet
Journal:  Vaccine       Date:  2014-02-25       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.